To date, only gilteritinib has been approved globally as a single agent for patients with relapsed/refractory FLT3-mutated AML [19], and it has demonstrated significant clinical efficacy but has been limited by the emergence of drug resistance. Here, FLT3 is linked to acute myeloid leukemia.